- Latest available (Revised)
- Original (As adopted by EU)
Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (Text with EEA relevance) (revoked)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
There are currently no known outstanding effects for the Commission Regulation (EC) No 1234/2008.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
CHAPTER IIa VARIATIONS TO PURELY NATIONAL MARKETING AUTHORISATIONS
Article 13a.Notification procedure for minor variations of type IA
Article 13b.Notification procedure for minor variations of type IB
Article 13c.‘Prior Approval’ procedure for major variations of type II
Article 13d.Grouping of variations to purely national marketing authorisations
Article 13e.Measures to close the procedures of Articles 13a to 13c
CHAPTER III VARIATIONS TO CENTRALISED MARKETING AUTHORISATIONS
SECTION 2 Amendments to the decision granting the marketing authorisation and implementation
Cases for grouping variations referred to in Article 7(2)(b) and Article 13d(2)(b)
4. All variations in the group relate solely to changes of...
6. All variations in the group relate to a project intended...
7. All variations in the group are changes affecting the quality...
8. All variations in the group are changes to the pharmacovigilance...
9. All variations in the group are consequential to a given...
10. All variations in the group relate to the implementation of...
11. All variations in the group are consequential to the assessment...
12. All variations in the group are consequential to a given...
13. All variations in the group are consequential to a specific...
14. All variations in the group are consequential to a specific...
1. A list of all the marketing authorisations affected by the...
2. A description of all the variations submitted, including:
3. All necessary documents as listed in the guidelines referred to...
5. In the case of variations to centralised marketing authorisations, the...
6. In the case of variations to marketing authorisations granted by...
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: